Archive for April, 2009
Sepracor Inc. (Nasdaq: SEPR) today announced that it has completed the analysis and validation of the preliminary results of a Phase II, 440-patient study evaluating the efficacy and safety of SEP-225441, a modified-release formulation of eszopiclone for the treatment of generalized anxiety disorder (GAD). Sepracor determined Read the rest of this entry »
Sufferers of post traumatic stress disorder (PTSD) are receiving specialized treatment from UMDNJ-University Behavioral HealthCare as a part of a National Institute of Mental Health study in collaboration with Dartmouth Medical School whose researchers adapted the treatment for people with serious mental illness.
Steven Silverstein, Ph.D., director and Stephanie Marcello, Ph.D., both of the Division Read the rest of this entry »